PLK1 and cancer: And as a result, a cohort of APCCdh1 substrates, including Plk1, Cdc6, Skp2, cyclin A, are eliminated, which eventually helps to amplify and sustain the anti-cancer function of these inhibitors (Supplementary Fig. 9h).